Market Cap 6.44B
Revenue (ttm) 2.57B
Net Income (ttm) -1.84B
EPS (ttm) N/A
PE Ratio 22.42
Forward PE 25.46
Profit Margin -71.86%
Debt to Equity Ratio 0.18
Volume 413,200
Avg Vol 383,148
Day's Range N/A - N/A
Shares Out 27.21M
Stochastic %K 86%
Beta 0.93
Analysts Sell
Price Target $313.40

Company Profile

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, q...

Industry: Medical Devices
Sector: Healthcare
Phone: 510 724 7000
Fax: 510 741 5817
Address:
1000 Alfred Nobel Drive, Hercules, United States
_CCS_
_CCS_ Jun. 23 at 7:53 PM
$BIO bull trap after trap
0 · Reply
leavens123
leavens123 May. 28 at 2:01 PM
$VERU not a matter of if, it’s when. This is bound to pass phase 2 and clinical. GLP1 is everywhere now. So muscle wasting from its use will need this big time. $SPRB $BIO $SBIO
0 · Reply
DerEins
DerEins May. 27 at 6:11 PM
$BIO Earnings have been good, upbeat the expected by 40%, the way down has been long for this now, if i look at the charts, a turningpoint might come.... so i jumped in today a bit, lets see how good my guess will be :-)
0 · Reply
SamwiseTheBrave
SamwiseTheBrave May. 19 at 3:24 PM
$SPY $BIO has decided not to eat it 🤣
0 · Reply
Bgarr231
Bgarr231 May. 7 at 11:31 PM
$BIO debating if i should avg down here or not...
0 · Reply
JarvisFlow
JarvisFlow May. 2 at 11:00 PM
UBS has updated their rating for Bio-Rad Laboratories ( $BIO ) to Buy with a price target of 310.
0 · Reply
JarvisFlow
JarvisFlow May. 2 at 10:30 PM
Citigroup has updated their rating for Bio-Rad Laboratories ( $BIO ) to Buy with a price target of 350.
0 · Reply
ChessGM
ChessGM Apr. 30 at 3:42 AM
Heads up alert! Only two days until Upcoming earnings on Thursday, 5/1/2025 for $BIO Bearish (2.5) In evaluating Bio-Rad Laboratories, Inc. (BIO), recent developments highlight a challenging financial landscape for the company. Analysts anticipate a decline in earnings for the upcoming quarter, which raises concerns about the company’s ability to meet investor expectations. The stock has seen a significant downturn, dropping 5% in the recent week and accumulating a staggering 61% loss over the past three years. This sustained underperformance is reflective of broader market trends and specific operational challenges within the company. Financial metrics indicate that Bio-Rad's P/E ratio may not be favorable compared to its peers, which typically hovers around the industry average of 20-25. Additionally, its EPS growth has been sluggish, contributing to a lack of investor confidence. Revenue forecasts have also been tempered, as the market anticipates a challenging environment ahead. Comparatively, Bio-Rad's competitors are showing more robust financial health, further complicating its market position. Upcoming earnings reports are crucial for Bio-Rad, with the company set to disclose its first-quarter financial results on May 1, 2025. Analysts have expressed skepticism about its ability to deliver positive surprises, given the current trends and historical performance, which has seen mixed results in recent quarters. The consensus estimate suggests a decrease in earnings per share, further influencing the overall sentiment toward the stock. Investors are advised to closely monitor management's guidance during the earnings call, as any positive indications could potentially mitigate some of the bearish sentiment surrounding the stock. However, based on current insights and expectations, the outlook remains fraught with challenges, suggesting a cautious approach to investment in BIO at this time. - Funds were net buyers of $BIO during the previous reporting quarter. - Top 1 funds with large holdings in $BIO: * Balyasny Asset Management LLC $15MM. New position. CGMFundRank: 92%, Fund Website: www.bamfunds.com - Last 10 days performance: 2% - Last 30 days performance: 0% - Last 90 days performance: -32% Follow ChessGM on stocktwits.com to get timely earnings alerts. Not a financial advice. Not a trading signal.
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Apr. 29 at 7:15 PM
Biomarkers market surging to $130B by 2029 – $BIO named a leader but needs to fix margins. High growth sector meets messy financials. Can they capitalize or get left behind? https://www.prnewswire.com/news-releases/biomarkers-market-to-grow-at-13-1-cagr-from-2024-to-2029--302441729.html
0 · Reply
REV007
REV007 Apr. 23 at 3:19 PM
0 · Reply
Latest News on BIO
Bio-Rad Reports First-Quarter 2025 Financial Results

May 1, 2025, 4:15 PM EDT - 7 weeks ago

Bio-Rad Reports First-Quarter 2025 Financial Results


Bio-Rad Laboratories, Inc. (BIO) Q4 2024 Earnings Call Transcript

Feb 13, 2025, 11:45 PM EST - 4 months ago

Bio-Rad Laboratories, Inc. (BIO) Q4 2024 Earnings Call Transcript


Bio-Rad Reports Third-Quarter 2024 Financial Results

Oct 30, 2024, 4:15 PM EDT - 8 months ago

Bio-Rad Reports Third-Quarter 2024 Financial Results


Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer

Aug 20, 2024, 8:30 AM EDT - 11 months ago

Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer


Bio-Rad Laboratories, Inc. (BIO) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 10:47 PM EDT - 11 months ago

Bio-Rad Laboratories, Inc. (BIO) Q2 2024 Earnings Call Transcript


Bio-Rad Reports Second-Quarter 2024 Financial Results

Aug 1, 2024, 4:15 PM EDT - 11 months ago

Bio-Rad Reports Second-Quarter 2024 Financial Results


Bio-Rad Reports First-Quarter 2024 Financial Results

May 7, 2024, 4:15 PM EDT - 1 year ago

Bio-Rad Reports First-Quarter 2024 Financial Results


Bio-Rad Announces Life Science Group Management Changes

Apr 26, 2024, 8:30 AM EDT - 1 year ago

Bio-Rad Announces Life Science Group Management Changes


Bio-Rad's Chief Operating Officer Andrew Last to Retire

Apr 10, 2024, 4:15 PM EDT - 1 year ago

Bio-Rad's Chief Operating Officer Andrew Last to Retire


Bio Rad Labs rises after posting upbeat fourth-quarter profit

Feb 15, 2024, 6:51 PM EST - 1 year ago

Bio Rad Labs rises after posting upbeat fourth-quarter profit


S&P 500 Stocks With the Most Upside

Dec 26, 2023, 11:29 AM EST - 1 year ago

S&P 500 Stocks With the Most Upside

APA APTV FSLR GM HAL LVS MRNA


6 Stock Picks in Healthcare for 2024

Dec 20, 2023, 3:07 PM EST - 1 year ago

6 Stock Picks in Healthcare for 2024

BMY CI HUM INCY MRNA


Bio-Rad Reports Third-Quarter 2023 Financial Results

Oct 26, 2023, 4:15 PM EDT - 1 year ago

Bio-Rad Reports Third-Quarter 2023 Financial Results


Bio-Rad: A Cash Flow Returns On Investments Analysis

Aug 10, 2023, 7:03 AM EDT - 2 years ago

Bio-Rad: A Cash Flow Returns On Investments Analysis


Bio-Rad Reports Second-Quarter 2023 Financial Results

Aug 3, 2023, 4:15 PM EDT - 2 years ago

Bio-Rad Reports Second-Quarter 2023 Financial Results


_CCS_
_CCS_ Jun. 23 at 7:53 PM
$BIO bull trap after trap
0 · Reply
leavens123
leavens123 May. 28 at 2:01 PM
$VERU not a matter of if, it’s when. This is bound to pass phase 2 and clinical. GLP1 is everywhere now. So muscle wasting from its use will need this big time. $SPRB $BIO $SBIO
0 · Reply
DerEins
DerEins May. 27 at 6:11 PM
$BIO Earnings have been good, upbeat the expected by 40%, the way down has been long for this now, if i look at the charts, a turningpoint might come.... so i jumped in today a bit, lets see how good my guess will be :-)
0 · Reply
SamwiseTheBrave
SamwiseTheBrave May. 19 at 3:24 PM
$SPY $BIO has decided not to eat it 🤣
0 · Reply
Bgarr231
Bgarr231 May. 7 at 11:31 PM
$BIO debating if i should avg down here or not...
0 · Reply
JarvisFlow
JarvisFlow May. 2 at 11:00 PM
UBS has updated their rating for Bio-Rad Laboratories ( $BIO ) to Buy with a price target of 310.
0 · Reply
JarvisFlow
JarvisFlow May. 2 at 10:30 PM
Citigroup has updated their rating for Bio-Rad Laboratories ( $BIO ) to Buy with a price target of 350.
0 · Reply
ChessGM
ChessGM Apr. 30 at 3:42 AM
Heads up alert! Only two days until Upcoming earnings on Thursday, 5/1/2025 for $BIO Bearish (2.5) In evaluating Bio-Rad Laboratories, Inc. (BIO), recent developments highlight a challenging financial landscape for the company. Analysts anticipate a decline in earnings for the upcoming quarter, which raises concerns about the company’s ability to meet investor expectations. The stock has seen a significant downturn, dropping 5% in the recent week and accumulating a staggering 61% loss over the past three years. This sustained underperformance is reflective of broader market trends and specific operational challenges within the company. Financial metrics indicate that Bio-Rad's P/E ratio may not be favorable compared to its peers, which typically hovers around the industry average of 20-25. Additionally, its EPS growth has been sluggish, contributing to a lack of investor confidence. Revenue forecasts have also been tempered, as the market anticipates a challenging environment ahead. Comparatively, Bio-Rad's competitors are showing more robust financial health, further complicating its market position. Upcoming earnings reports are crucial for Bio-Rad, with the company set to disclose its first-quarter financial results on May 1, 2025. Analysts have expressed skepticism about its ability to deliver positive surprises, given the current trends and historical performance, which has seen mixed results in recent quarters. The consensus estimate suggests a decrease in earnings per share, further influencing the overall sentiment toward the stock. Investors are advised to closely monitor management's guidance during the earnings call, as any positive indications could potentially mitigate some of the bearish sentiment surrounding the stock. However, based on current insights and expectations, the outlook remains fraught with challenges, suggesting a cautious approach to investment in BIO at this time. - Funds were net buyers of $BIO during the previous reporting quarter. - Top 1 funds with large holdings in $BIO: * Balyasny Asset Management LLC $15MM. New position. CGMFundRank: 92%, Fund Website: www.bamfunds.com - Last 10 days performance: 2% - Last 30 days performance: 0% - Last 90 days performance: -32% Follow ChessGM on stocktwits.com to get timely earnings alerts. Not a financial advice. Not a trading signal.
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Apr. 29 at 7:15 PM
Biomarkers market surging to $130B by 2029 – $BIO named a leader but needs to fix margins. High growth sector meets messy financials. Can they capitalize or get left behind? https://www.prnewswire.com/news-releases/biomarkers-market-to-grow-at-13-1-cagr-from-2024-to-2029--302441729.html
0 · Reply
REV007
REV007 Apr. 23 at 3:19 PM
0 · Reply
Poordaddy20
Poordaddy20 Apr. 20 at 12:00 AM
$BIO what are the chances these bastards go chapter 7 and the sell to Eli Lilly for diabetic medicine. I see Eli has past late stage trials with a pill form. Adi you are a SOB cheating everyone karma is a bitch.
1 · Reply
REV007
REV007 Apr. 17 at 10:07 PM
$APDN rumor of potential $BIO buyout #StayTuned
3 · Reply
JarvisFlow
JarvisFlow Apr. 17 at 3:51 PM
Wells Fargo has updated their rating for Bio-Rad Laboratories ( $BIO ) to Equal-Weight with a price target of 270.
0 · Reply
TheAncientLanguageOf1_9
TheAncientLanguageOf1_9 Mar. 24 at 8:38 PM
$BIO - above $280 by end of March - above $340 by end of April - after that we shall see
1 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 24 at 7:22 PM
$BIO Digging the digital PCR play. Stilla acquisition looks strategic. Might be a good long-term bet on life sciences innovation. Watching closely. engaging article: https://beyondspx.com/article/bio-rad-laboratories-inc-bio-a-versatile-powerhouse-in-the-life-sciences-and-diagnostics-arenas
0 · Reply
only1mc
only1mc Mar. 24 at 1:19 AM
$PSTV $HOLO $BIO in these and have 👀 on $WGRX ... A lot of hype this weekend. Will be looking for another banger. I have a feeling tomorrow will be awesome!!!!! Let's find the money train tomorrow 🙏.
0 · Reply
BigPlaySnipers
BigPlaySnipers Mar. 20 at 10:11 PM
0 · Reply
gretaslaps
gretaslaps Mar. 20 at 10:00 PM
$GCTK crazy to sell here when you saw what $BIO just did… so wtf sold BIO at .50s????? lol
0 · Reply
kadixon
kadixon Mar. 11 at 1:45 AM
$BIO I guess I'm the only one buying at $250 ?
0 · Reply
swingingtech
swingingtech Mar. 4 at 3:10 PM
$USXF $BIO $HUBB $GEV https://wallstreetwaves.com/valuing-usxf-projected-price-of-60-in-focus/
0 · Reply
swingingtech
swingingtech Mar. 3 at 2:43 PM
$TMO $BIO https://wallstreetwaves.com/evaluating-thermo-fisher-scientifics-stock-performance-against-the-sp-500/
0 · Reply
RadioIsotope25
RadioIsotope25 Mar. 2 at 8:04 PM
$RADX Lantheus a big partner for Radiopharma Theranostics invested last round at over 100% of current price $11+ now at $5$IMNM $SMMT $BIO
1 · Reply